ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a ...

Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...

The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.

EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...

A diagnosis of adenocarcinoma of the bladder requires careful and specialized care. Because it is rare, it is essential to be treated by a multidisciplinary team, including a urologic oncologist, ...

Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Urological surgeons warn of a significant and worrying rise in bladder cancer in Nigeria, urging for greater public awareness ...

Recognizing common bladder cancer symptoms, such as blood in urine, can help you identify this disease in its early stages, when it may be more treatable.